Brief: GeNeuro And Ciri Expand Focus To Post-COVID Syndromes

Geneuro SA

24/06/2021 06:32

June 24 (Reuters) - GENEURO SA  GNRO.PA :
    * GENEURO AND CIRI RENEW COLLABORATION AGREEMENT AND EXPAND
FOCUS
TO POST-COVID SYNDROMES
    * GENEURO AND CIRI RENEW COLLABORATION AGREEMENT AND EXPAND
FOCUS
TO POST-COVID SYNDROMES
    * NEW FOCUS EXPANDED TO INVESTIGATE LINK BETWEEN HERV-W ENV
AND
LONG-TERM DAMAGE, IN PARTICULAR NEUROLOGICAL, EXPERIENCED BY
POST-COVID-19 PATIENTS
    * HERV-W ENV MAY PROVIDE BIOLOGICAL RATIONALE WITH TEMELIMAB
PROVIDING THERAPEUTIC OPTION FOR POST-COVID-19 NEUROLOGICAL AND
PSYCHIATRIC SYNDROMES
    * GENEURO'S TEMELIMAB, WHICH HAS ALREADY PROVEN ITS
EXCELLENT
TOLERABILITY IN PHASE 2 TRIALS, COULD BE MADE IMMEDIATELY
AVAILABLE FOR A CLINICAL TRIAL IN POST-COVID

Source text for Eikon:  ID:nBwJbxZ5a 
Further company coverage:  GNRO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))